Clinical Trials

176 enrolled

Pancreatic Neoplasms

NCT06835387 2026-02-17

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

36 enrolled

Small Bowel Adenocarcinoma

NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

224 enrolled

Biliary Tract Neoplasms, Stomach Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

48 enrolled

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT07281157 2025-12-30

Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

30 enrolled

Advanced Colorectal Cancer

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Colorectal Cancer Metastatic

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

328 enrolled

Pancreatic Neoplasms

NCT04656041 2025-11-14

Folfox+Irinotecan+Chemort In Esophageal Cancer

40 enrolled

Gastroesophageal Junction Adenocarcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

135 enrolled

Sarcoma

Rhabdomyosarcoma

NCT07123441 2025-08-14

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

300 enrolled

Colorectal Neoplasms

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

33 enrolled

Stomach Neoplasms

NCT03693677 2025-07-01

FUNGEMAX

288 enrolled

Pancreatic Neoplasms

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT05854498 2025-06-12

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

25 enrolled

Colorectal Neoplasms

NCT07004712 2025-06-08

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

46 enrolled

Small Cell Lung Carcinoma

NCT06827717 2025-05-31

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

29 enrolled

Sarcoma

Sarcoma, Ewing

NCT06438822 2025-05-07

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

51 enrolled

Cholangiocarcinoma

NCT03328884 2025-04-23

Phenomenal

55 enrolled

Breast

Breast Cancer Metastatic

NCT03861702 2025-04-18

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

28 enrolled 20 charts

Locally Advanced Pancreatic Carcinoma(LAPC)

NCT06210971 2025-03-13

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

60 enrolled

Rectal Neoplasms

NCT03736720 2025-01-30

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Phase 2 Terminated

11 enrolled 17 charts

Somatostatinoma

NCT06643793 2025-01-28

Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC

30 enrolled

Colonic Neoplasms

NCT06657690 2025-01-10

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

56 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

47 enrolled

Pancreatic Neoplasms

NCT03719924 2025-01-08

OESIRI

106 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03837977 2024-12-30

NET02

58 enrolled

Endocrine

Neoplasms, Carcinoma, Neuroendocrine

NCT06749691 2024-12-27

LIAES

30 enrolled

Small Cell Lung Carcinoma

NCT06739928 2024-12-18

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

120 enrolled

Small Cell Lung Cancer Extensive Stage

NCT05859750 2024-12-16

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

78 enrolled

Pancreatic Neoplasms

NCT06405139 2024-11-29

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

36 enrolled

Colorectal Neoplasms

NCT06700603 2024-11-22

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

48 enrolled

Pancreatic Neoplasms

NCT06697366 2024-11-20

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

27 enrolled

Stomach Neoplasms

NCT02826486 2024-08-28

COMBAT

80 enrolled 13 charts

Metastatic Pancreatic Adenocarcinoma

NCT06341296 2024-08-12

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

86 enrolled

Colorectal Neoplasms

NCT06531278 2024-07-31

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

40 enrolled

Pancreatic Cancer Metastatic to Liver

NCT02697058 2024-07-25

Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer

84 enrolled

Pancreatic Neoplasms

NCT03336216 2024-07-23

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

205 enrolled 30 charts

Advanced Pancreatic Cancer

NCT05009953 2024-07-11

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Phase 2 Terminated

17 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04727853 2024-07-10

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

66 enrolled

Small Cell Lung Carcinoma

NCT06478043 2024-07-08

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

54 enrolled

Small Cell Lung Carcinoma

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

120 enrolled

Efficacy and Safety

NCT04371224 2024-04-19

NaliCap

200 enrolled

Pancreatic Neoplasms

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Phase 2 Unknown

40 enrolled

Borderline Resectable Pancreatic Cancer

NCT06192680 2024-01-18

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

63 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

134 enrolled

Pancreatic Neoplasms

NCT06172036 2023-12-15

CAPT-02

180 enrolled

Neoadjuvant Chemotherapy

NCT05363007 2023-10-16

SINAI

Phase 2 Unknown

60 enrolled

Pancreatic Neoplasms

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT03712397 2023-04-11

Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy